Columbia Laboratories, Inc. (NASDAQ: CBRX) today announced it has completed enrollment in its randomized, double-blind, placebo-controlled Phase III study of Prochieve(R) 8% (progesterone gel) for a new indication, the prevention of preterm birth. This large-scale global trial involves over 600 patients at more than 60 centers throughout the United States, Europe, South America, Asia and South Africa. It is designed to assess the ability of Prochieve(R) 8% to safely, effectively and tolerably prevent preterm birth in pregnant women who are predisposed to this problem. Prochieve(R) 8% is currently FDA-approved and commercially available to treat infertility and secondary amenorrhea.
